Case-control study on concentrations of organohalogen compounds and titers of antibodies to Epstein-Barr virus antigens in the etiology of non-Hodgkin lymphoma.

Abstract:

:A rapid increase in incidence of non-Hodgkin lymphoma (NHL) has been reported from many countries. Exposure to certain pesticides and organochlorines has been shown to be risk factors. Epstein-Barr virus (EBV) is a human herpesvirus that has been associated with some subgroups of NHL, such as Burkitt lymphoma and lymphomas related to severe immunosuppression. In this study, we measured lipid adjusted blood concentrations of 36 congeners of polychlorinated biphenyls (PCBs), p,p'-dichlorodiphenyl-dichloroethylene (p,p'-DDE), hexachlorobenzene (HCB), four different subgroups of chlordanes (trans-nonachlordane, cis-nonachlordane, MC6 and oxychlordane) and 2,2',4,4'-tetrabrominated diphenyl ether (TBDE) in incident cases of NHL and controls from the general population. Titers of antibodies to the Epstein-Barr early antigen (EA) were correlated to concentrations of organochlorines. We found a significant difference in lipid adjusted blood concentrations of total PCBs and TBDE between cases and controls. Titers of antibodies to EA IgG > 80 were correlated to an increased risk for NHL with odds ratio (OR) = 1.9, 95% confidence interval (CI) =0.94-3.8. This risk was further increased in those with a level above the median value of "sum of PCBs" (OR=4.0, CI=1.2-14), HCB (OR=5.3, CI=1.6-19), sum of chlordanes (OR=4.0, CI=1.2-14) and TBDE (OR=21, CI=4.6-124), suggesting an interaction between EBV and a higher concentration of these chemicals. Also for the "sum of immunotoxic PCBs" increased risk was found in that group (OR=6.4, CI=1.9-24). Subdivision of NHL in histological types yielded highest risks for low-grade B-cell NHL.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Hardell E,Eriksson M,Lindström G,Van Bavel B,Linde A,Carlberg M,Liljegren G

doi

10.3109/10428190109099322

keywords:

subject

Has Abstract

pub_date

2001-08-01 00:00:00

pages

619-29

issue

4

eissn

1042-8194

issn

1029-2403

journal_volume

42

pub_type

杂志文章
  • Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia.

    abstract::Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem cell disorder that is characterized by florid bone marrow stromal reaction including collagen fibrosis, osteosclerosis, and angiogenesis. Almost all patients with MMM display increased bone marrow microvessel density (MVD) and the extent is among the highest...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190400003267

    authors: Arora B,Mesa R,Tefferi A

    更新日期:2004-12-01 00:00:00

  • The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL).

    abstract::The emergence of radioimmunotherapy (RIT) provides a new therapeutic approach in which monoclonal antibodies directed against tumor-specific antigens are used to target therapeutic radioisotopes to sites of disseminated disease. The target cell is eliminated and adjacent tumor cells, to which antibody has not bound, a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428140310001616935

    authors: Bischof Delaloye A

    更新日期:2003-01-01 00:00:00

  • Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma.

    abstract::Multiple myeloma is a genetically heterogenous disease with a wide variety of characterized genetic aberrations. Until recently, the impact of these aberrations on patient outcome was not known. However, in the last 5-10 years, several genetic markers have been linked to patient outcome. One of the strongest predictor...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190600822128

    authors: Keats JJ,Reiman T,Belch AR,Pilarski LM

    更新日期:2006-11-01 00:00:00

  • Genomic stratification of multiple myeloma treated with novel agents.

    abstract::Cytogenetic testing is now routinely performed for the prognostic work-up of multiple myeloma (MM). The abnormalities del(17p), t(4;14) and del(13q) have been established as predictors of poor outcome in patients with MM treated with conventional chemotherapy or stem cell transplant; chromosome 1q gains and 1p losses ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2011.608449

    authors: Jiang A,Reece D,Chang H

    更新日期:2012-02-01 00:00:00

  • Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression.

    abstract::Recent data have suggested that rituximab is an active agent for the treatment of Waldenstrom's macroglobulinemia (WM). However, the patients that are more likely to benefit have not been clearly defined. In order to address this question we evaluated 52 patients who were treated with single-agent rituximab in the con...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.1080/10428190410001723287

    authors: Dimopoulos MA,Alexanian R,Gika D,Anagnostopoulos A,Zervas C,Zomas A,Kyrtsonis MC,Anagnostopoulos N,Pangalis GA,Weber DM

    更新日期:2004-10-01 00:00:00

  • Epidemiology of myeloproliferative neoplasms in the United States.

    abstract::Myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) are three classic BCR ABL fusion gene-negative chronic myeloproliferative neoplasms (MPNs). Though rare, it is important to understand the burden of illness of these disorders for public health planning, healthcare insurers and pharmaceutica...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.813500

    authors: Mehta J,Wang H,Iqbal SU,Mesa R

    更新日期:2014-03-01 00:00:00

  • Cigarette smoking is associated with a small increase in the incidence of non-Hodgkin lymphoma: a meta-analysis of 24 observational studies.

    abstract::Previous studies have evaluated the association between cigarette smoking and incidence of non-Hodgkin lymphoma (NHL) with inconclusive results. Our main objective was to evaluate this relationship using a meta-analysis of observational studies. A literature search was undertaken through October 2011 looking for perti...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,meta分析

    doi:10.3109/10428194.2012.673225

    authors: Castillo JJ,Dalia S

    更新日期:2012-10-01 00:00:00

  • Vincristine degradation by serum from leukemic patients: role of myeloperoxidase.

    abstract::Myeloperoxidase (MPO) has been shown to catalyze the in vitro degradation of vincristine (VCR). Given that MPO is a lysosomal enzyme that can be released into the circulation by both normal activated and leukemic myeloid cells, we investigated the possibility that sera from patients with acute myeloblastic leukemia (A...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199609052426

    authors: Schlaifer D,Duchayne E,Demur C,Alvinerie P,Muller C,Attal M,Cooper MR,Payen C,Monsarrat B,Myers CE,Pris J,Laurent G

    更新日期:1996-02-01 00:00:00

  • Prognostic significance of the Bcl-2 negative germinal centre in patients with diffuse large B cell lymphoma treated with R-CHOP.

    abstract::The classification of germinal centre (GC) and non-GC is an important prognostic immunophenotype for patients with diffuse large B cell lymphoma (DLBCL) following anthracycline-based chemotherapy. The expression of the anti-apoptotic protein, Bcl-2, has been associated with an unfavourable prognosis in patients with D...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190802626616

    authors: Song MK,Chung JS,Shin DH,Seol YM,Shin HJ,Choi YJ,Cho GJ

    更新日期:2009-01-01 00:00:00

  • Fertility status among women treated for aggressive non-Hodgkin's lymphoma.

    abstract::In young women treated for intermediate-high-grade non-Hodgkin's lymphoma with CHOP (cyclophosphamide, adriamycin, oncovine and prednisone), there is insufficient data concerning gonadotoxicity or the need for fertility-preserving measures. The aim of the present study was to evaluate the fertility status in the first...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500353877

    authors: Elis A,Tevet A,Yerushalmi R,Blickstein D,Bairy O,Dann EJ,Blumenfeld Z,Abraham A,Manor Y,Shpilberg O,Lishner M

    更新日期:2006-04-01 00:00:00

  • Response to hyperfractionated accelerated radiotherapy in chemotherapy-refractory non-Hodgkin lymphoma.

    abstract::Patients with chemotherapy-refractory non-Hodgkin lymphoma (NHL) have a poor prognosis with a median overall survival (OS) of only 10 months. To investigate the role of radiotherapy (RT) in such patients, we conducted a retrospective review of 17 patients with biopsy-proven refractory NHL who received hyperfractionate...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1719096

    authors: Kim DW,Lee G,Lee H,Mahal AR,Lam MB,Ng AK

    更新日期:2020-06-01 00:00:00

  • Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?

    abstract::The significant clinical activity of lenalidomide in relapsed CLL was first described several years ago. Since then the problems of tumor flare and tumor lysis have emerged, and upfront single agent studies have reported response rates that were perhaps a little disappointing. Interest in elucidating the place of lena...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.496017

    authors: Brown JR

    更新日期:2010-08-01 00:00:00

  • Primary gastric lymphoma: utility of 18F-fluorodeoxyglucose positron emission tomography-computed tomography for detecting relapse after treatment.

    abstract::The purpose of this study was to evaluate the role of 18F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography-computed tomography (PET-CT) in detecting relapse in patients with primary gastric lymphoma (PGL) post-treatment. Data of 39 previously treated patients with PGL (age: 50.3 ± 13.8 years; male: 24) who ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.717694

    authors: Sharma P,Suman SK,Singh H,Sharma A,Bal C,Malhotra A,Kumar R

    更新日期:2013-05-01 00:00:00

  • Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction.

    abstract::After a first course of induction chemotherapy, 30-40% of patients with acute myeloid leukemia (AML) do not achieve a complete response (CR). A second course of an anthracycline and intermediate-dose cytarabine (IDAC) allows a significant number of patients with persistent AML at day 14 to finally achieve a CR. We hyp...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.685733

    authors: Prébet T,Jean E,Autret A,Charbonnier A,Rey J,Etienne A,D'incan E,Fürst S,Arnoulet C,Blaise D,Vey N

    更新日期:2012-11-01 00:00:00

  • Use of hematopoietic progenitor cell count on the Sysmex XE-2100 for peripheral blood stem cell harvest monitoring.

    abstract::Successful peripheral blood stem cell (PBSC) collection depends on the timing of apheresis based on CD34+ cell enumeration. Because this analysis is expensive and induces organization difficulties, we evaluated hematopoietic progenitor cell (HPC) quantification on the Sysmex XE-2100 as a surrogate analysis. We tested ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600886149

    authors: Letestu R,Marzac C,Audat F,Belhocine R,Tondeur S,Baccini V,Garçon L,Cortivo LD,Perrot JY,Lefrère F,Valensi F,Ajchenbaum-Cymbalista F

    更新日期:2007-01-01 00:00:00

  • Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.

    abstract::Blinatumomab is a member of a novel class of T cell-engaging bispecific antibodies, so-called Bispecific T cell Engager (BiTEs). It is directed against the B cell differentiation antigen CD19 and intended for treatment of B cell malignancies. In clinical phase I/II trials, blinatumomab showed remarkable single-agent a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2016.1161185

    authors: Goebeler ME,Bargou R

    更新日期:2016-05-01 00:00:00

  • Gastrointestinal Non-Hodgkin's Lymphoma.

    abstract::The records of 77 patients with gastrointestinal Non-Hodgkin's Lymphoma (GI-NHL) diagnosed from 1972 to 1988 were reviewed. There were 47 male and 30 female patients, median age 56 years (range 20-82 years). Twenty-four patients had stage I disease at presentation, 25 stage II, 8 stage III and 20 stage IV. The primary...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109068062

    authors: Stewart AK,Shepherd FA,Goss PE,Warner E,Bailey DJ,Baker MA

    更新日期:1991-01-01 00:00:00

  • Interferon treatment for hairy cell leukemia. An update on a cohort of 69 patients treated from 1983 to 1986.

    abstract::We report follow-up information on 69 hairy cell leukemia (HCL) patients treated with interferon alfa-2b (IFN) as primary treatment from 1983 to 1986. Follow-up through April, 1993 shows that only 14 patients have expired. Forty-seven of the 61 patients completing the intended 12 or more months of initial IFN treatmen...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Spielberger RT,Mick R,Ratain MJ,Golomb HM

    更新日期:1994-01-01 00:00:00

  • Increased myeloid-derived suppressor cells in patients with myelodysplastic syndromes suppress CD8+ T lymphocyte function through the STAT3-ARG1 pathway.

    abstract::MDSCs, which are defined as a kind of negatively regulatory cells, could suppress T cell immune response in many tumor-bearing animal models and cancer patients. We supposed that MDSCs also contributed to the impaired antitumor immunity in MDS. Here we demonstrated that STAT3-ARG1 pathway could be a critical signal tr...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1817431

    authors: Qi X,Jiang H,Liu P,Xie N,Fu R,Wang H,Liu C,Zhang T,Wang H,Shao Z

    更新日期:2021-01-01 00:00:00

  • Analysis of WT1 mutations, expression levels and single nucleotide polymorphism rs16754 in de novo non-M3 acute myeloid leukemia.

    abstract::The single nucleotide polymorphism (SNP) rs16754 of the WT1 gene has been described as a possible prognostic marker in patients with acute myeloid leukemia (AML). However, the results in this field are not reproducible in different cohorts. In this study, we investigated WT1 mutations, expression levels and SNP rs1675...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.791985

    authors: Luo S,Yu K,Yan QX,Shen ZJ,Wu JB,Chen HM,Gao SM

    更新日期:2014-02-01 00:00:00

  • Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.

    abstract::Due to Cytochrome P450 3A (CYP3A) metabolism, clinical trials of ibrutinib-treated chronic lymphocytic leukemia (CLL) patients prohibited concurrent medications metabolized by CYP3A. We evaluated concomitant medication use in 118 ibrutinib-treated CLL patients outside the context of clinical trials. Seventy-five (64%)...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1251592

    authors: Finnes HD,Chaffee KG,Call TG,Ding W,Kenderian SS,Bowen DA,Conte M,McCullough KB,Merten JA,Bartoo GT,Smith MD,Leis J,Chanan-Khan A,Schwager SM,Slager SL,Kay NE,Shanafelt TD,Parikh SA

    更新日期:2017-06-01 00:00:00

  • Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin.

    abstract::We evaluated outcome of 235 primary treatment failure (PTF) diffuse large B-cell lymphoma (DLBCL) patients based on salvage chemotherapy regimen and putative cell-of-origin (COO). Patients were divided into two groups; group A (n = 38) received high-dose cytarabine containing regimen, either DHAP or ESHAP. Patients in...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1515944

    authors: Badar T,Hamadani M,Bachanova V,Maddocks KJ,Umyarova E,Chavez JC,Epperla N,Chhabra S,Xavier AC,Karmali R,Salhab M,Reddy N,Glenn MJ,Hernandez-Ilizaliturri FJ,Flowers CR,Evens AM,Zhou Z,Lansigan F,Barta SK,Cohen JB,F

    更新日期:2019-04-01 00:00:00

  • Monoclonal B-cell lymphocytosis: a reappraisal of its clinical implications.

    abstract::Monoclonal B-cell lymphocytosis (MBL) is a recently defined medical condition that displays biological similarities to chronic lymphocytic leukemia (CLL), the most common subtype of adult leukemia in the Western world. MBL may be diagnosed in individuals with a normal lymphocyte count via a screening assay (screening ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2012.666542

    authors: Molica S,Mauro FR,Molica M,Del Giudice I,Foà R

    更新日期:2012-09-01 00:00:00

  • Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.

    abstract::The prognostic significance of rare BCR-ABL1 transcripts is uncertain in the tyrosine kinase inhibitor (TKI) era. In this retrospective study, 40 (1.7%) patients with rare BCR-ABL1 transcripts were identified from a cohort of 2331 chronic myeloid leukemia (CML) patients; 4 types of rare transcripts were identified, in...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1607329

    authors: Xue M,Wang Q,Huo L,Wen L,Yang X,Wu Q,Pan J,Cen J,Ruan C,Wu D,Chen S

    更新日期:2019-12-01 00:00:00

  • Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study.

    abstract::Preliminary results indicate that inhibitors of the nuclear enzyme topoisomerase (topo) I, such as topotecan, may be active in non-Hodgkin's lymphoma (NHL). Pre-clinical studies have shown sequential administration of a topo I and II inhibitor has supra-additive anti-tumor effects in some model systems, and that great...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.1080/1042819021000002901

    authors: Crump M,Couban S,Meyer R,Rudinskas L,Zanke B,Gluck S,Maksymiuk A,Hoskins P,Matthews S,Eisenhauer E

    更新日期:2002-08-01 00:00:00

  • Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience.

    abstract::Isolated central nervous system (CNS) relapse was evaluated in terms of incidence, risk factors, and outcome in a consecutive cohort of 175 patients with aggressive non-Hodgkin's lymphoma in which no case of lymphoblastic or Burkitt's lymphoma was encountered. All these patients had obtained a complete remission with ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909058415

    authors: Zinzani PL,Magagnoli M,Frezza G,Prologo G,Gherlinzoni F,Bendandi M,Albertini P,Babini L,D'Alessandro R,Tura S

    更新日期:1999-02-01 00:00:00

  • Detection of simian virus 40 DNA sequences in Egyptian patients with different hematological malignancies.

    abstract::SV40 DNA sequences have been detected in non-Hodgkin's lymphoma patients. A link between SV40 and NHL is biologically plausible since SV40 causes hematological malignancies in laboratory rodents. We investigated 266 Egyptian cases of hematological malignancies (158 NHL, 54 HD, 26 ALL, 13 AML, 8 CLL, 7 CML) and 34 subj...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701534408

    authors: Zekri AR,Mohamed W,Bahnassy A,Refat L,Khaled M,Shalaby S,Hafez M

    更新日期:2007-09-01 00:00:00

  • The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy.

    abstract::We addressed the prognostic impact of cell-of-origin (COO), MYC and Bcl-2 overexpression as well as isolated MYC rearrangement among 111 patients with limited stage diffuse large B-cell lymphoma (DLBCL) treated with consolidative radiation therapy (RT) after a metabolic complete response to immunochemotherapy. With a ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1869965

    authors: Augustyn A,Medeiros LJ,Ludmir EB,Gunther J,Fang P,Li S,Ok CY,Bankston ME,Verma V,Pasalic D,Ahmed S,Nastoupil LJ,Westin JR,Strati P,Neelapu SS,Nair R,Steiner RE,Iyer SP,Rodriguez A,Fayad LE,Flowers CR,Dabaja BS,

    更新日期:2021-01-22 00:00:00

  • Gravin gene expression in acute leukaemias: clinical importance and review of the literature.

    abstract::The aim of this study was to determine the expression of Gravin (a tumor suppressor gene belonging to the A kinase anchoring protein family) in samples of acute leukaemia and to explore its association with the prognosis. The study group consisted of 162 people (137 patients with acute leukaemia and 25 volunteers as c...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190701377055

    authors: Yildirim M,Paydas S,Tanriverdi K,Seydaoglu G,Disel U,Yavuz S

    更新日期:2007-06-01 00:00:00

  • Down regulation of stem cell colony formation by purified CD8 lymphocytes and CD8 conditioned medium: potential importance for bone marrow transplantation in leukemia.

    abstract::A methodology for selection of the CD8 cell subset from the peripheral blood and bone marrow mononuclear cells was developed using anti-T8 (CD8) antibody and magnetic microspheres coated with anti-mouse IgG. Following optimization of antibody:cell binding ratio and microsphere:cell ratios, CD8(+)-cells in the peripher...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199209049825

    authors: Gazitt Y,He YJ

    更新日期:1992-09-01 00:00:00